157 related articles for article (PubMed ID: 33970615)
1. Safe Polycationic Dendrimers as Potent Oral In Vivo Inhibitors of
Mignani S; Tripathi VD; Soam D; Tripathi RP; Das S; Singh S; Gandikota R; Laurent R; Karpus A; Caminade AM; Steinmetz A; Dasgupta A; Srivastava KK; Majoral JP
Biomacromolecules; 2021 Jun; 22(6):2659-2675. PubMed ID: 33970615
[TBL] [Abstract][Full Text] [Related]
2. Polycationic phosphorous dendrimer potentiates multiple antibiotics against drug-resistant mycobacterial pathogens.
Imran M; Singh S; Ahmad MN; Malik P; Mukhopadhyay A; Yadav KS; Gupta UD; Mugale MN; Mitra K; Srivastava KK; Chopra S; Mignani S; Apartsin E; Majoral JP; Dasgupta A
Biomed Pharmacother; 2024 Apr; 173():116289. PubMed ID: 38452653
[TBL] [Abstract][Full Text] [Related]
3. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of DNF-3 against drug-resistant Mycobacterium tuberculosis.
Islam MI; Han CM; Seo H; Kim S; Mahmud HA; Nam KW; Lee BE; Sadu VS; Lee KI; Song HY
Int J Antimicrob Agents; 2019 Jul; 54(1):69-74. PubMed ID: 30807817
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of (-)-deoxypergularinine, on its own and in combination with anti-tubercular drugs, against resistant strains of Mycobacterium tuberculosis.
Nam KW; Jang WS; Jyoti MA; Kim S; Lee BE; Song HY
Phytomedicine; 2016 May; 23(5):578-82. PubMed ID: 27064017
[TBL] [Abstract][Full Text] [Related]
6. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and investigation on the structure-activity relationships of N-substituted 2-aminothiazole derivatives as antitubercular agents.
Pieroni M; Wan B; Cho S; Franzblau SG; Costantino G
Eur J Med Chem; 2014 Jan; 72():26-34. PubMed ID: 24333612
[TBL] [Abstract][Full Text] [Related]
8. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
9. Naphthoquinones isolated from Diospyros anisandra exhibit potent activity against pan-resistant first-line drugs Mycobacterium tuberculosis strains.
Uc-Cachón AH; Borges-Argáez R; Said-Fernández S; Vargas-Villarreal J; González-Salazar F; Méndez-González M; Cáceres-Farfán M; Molina-Salinas GM
Pulm Pharmacol Ther; 2014 Feb; 27(1):114-20. PubMed ID: 23968826
[TBL] [Abstract][Full Text] [Related]
10. A New Screen for Tuberculosis Drug Candidates Utilizing a Luciferase-Expressing Recombinant Mycobacterium bovis Bacillus Calmette-Guéren.
Ozeki Y; Igarashi M; Doe M; Tamaru A; Kinoshita N; Ogura Y; Iwamoto T; Sawa R; Umekita M; Enany S; Nishiuchi Y; Osada-Oka M; Hayashi T; Niki M; Tateishi Y; Hatano M; Matsumoto S
PLoS One; 2015; 10(11):e0141658. PubMed ID: 26571296
[TBL] [Abstract][Full Text] [Related]
11. Evolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-Natal.
Cohen KA; Abeel T; Manson McGuire A; Desjardins CA; Munsamy V; Shea TP; Walker BJ; Bantubani N; Almeida DV; Alvarado L; Chapman SB; Mvelase NR; Duffy EY; Fitzgerald MG; Govender P; Gujja S; Hamilton S; Howarth C; Larimer JD; Maharaj K; Pearson MD; Priest ME; Zeng Q; Padayatchi N; Grosset J; Young SK; Wortman J; Mlisana KP; O'Donnell MR; Birren BW; Bishai WR; Pym AS; Earl AM
PLoS Med; 2015 Sep; 12(9):e1001880. PubMed ID: 26418737
[TBL] [Abstract][Full Text] [Related]
12. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
13. Activity of a new class of isonicotinoylhydrazones used alone and in combination with isoniazid, rifampicin, ethambutol, para-aminosalicylic acid and clofazimine against Mycobacterium tuberculosis.
De Logu A; Onnis V; Saddi B; Congiu C; Schivo ML; Cocco MT
J Antimicrob Chemother; 2002 Feb; 49(2):275-82. PubMed ID: 11815568
[TBL] [Abstract][Full Text] [Related]
14. Mefloquine and its oxazolidine derivative compound are active against drug-resistant Mycobacterium tuberculosis strains and in a murine model of tuberculosis infection.
Rodrigues-Junior VS; Villela AD; Gonçalves RS; Abbadi BL; Trindade RV; López-Gavín A; Tudó G; González-Martín J; Basso LA; de Souza MV; Campos MM; Santos DS
Int J Antimicrob Agents; 2016 Aug; 48(2):203-7. PubMed ID: 27364701
[TBL] [Abstract][Full Text] [Related]
15. Molecular Screening Versus Phenotypic Susceptibility Testing of Multidrug-Resistant Mycobacterium tuberculosis Isolates for Streptomycin and Ethambutol.
Al-Mutairi NM; Ahmad S; Mokaddas E
Microb Drug Resist; 2018 Sep; 24(7):923-931. PubMed ID: 29336677
[TBL] [Abstract][Full Text] [Related]
16. Synergy between Circular Bacteriocin AS-48 and Ethambutol against Mycobacterium tuberculosis.
Aguilar-Pérez C; Gracia B; Rodrigues L; Vitoria A; Cebrián R; Deboosère N; Song OR; Brodin P; Maqueda M; Aínsa JA
Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29987141
[TBL] [Abstract][Full Text] [Related]
17. In vitro bactericidal activity of 3-cinnamoyl-4-hydroxy-6-methyl-2-pyrone (CHP) against drug-susceptible, drug-resistant and drug-tolerant isolates of Mycobacterium tuberculosis.
Bhat ZS; Rather MA; Ul Lah H; Hussain A; Maqbool M; Yousuf SK; Jabeen Z; Wani MA; Ahmad Z
J Glob Antimicrob Resist; 2020 Sep; 22():57-62. PubMed ID: 31809940
[TBL] [Abstract][Full Text] [Related]
18. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super extensively drug-resistant tuberculosis or totally drug-resistant strains in iran.
Velayati AA; Masjedi MR; Farnia P; Tabarsi P; Ghanavi J; ZiaZarifi AH; Hoffner SE
Chest; 2009 Aug; 136(2):420-425. PubMed ID: 19349380
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of fourteen antimicrobial agents against drug susceptible and resistant clinical isolates of Mycobacterium tuberculosis and comparative intracellular activities against the virulent H37Rv strain in human macrophages.
Rastogi N; Labrousse V; Goh KS
Curr Microbiol; 1996 Sep; 33(3):167-75. PubMed ID: 8672093
[TBL] [Abstract][Full Text] [Related]
20. Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.
Clemens DL; Lee BY; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
PLoS One; 2019; 14(5):e0215607. PubMed ID: 31075149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
